These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39402448)

  • 21. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.
    Hawi A; Alcorn H; Berg J; Hines C; Hait H; Sciascia T
    BMC Nephrol; 2015 Apr; 16():47. PubMed ID: 25885112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
    Kim BS; Bissonnette R; Nograles K; Munera C; Shah N; Jebara A; Cirulli J; Goncalves J; Lebwohl M;
    N Engl J Med; 2023 Feb; 388(6):511-517. PubMed ID: 36780675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.
    Fishbane S; Wen W; Munera C; Lin R; Bagal S; McCafferty K; Menzaghi F; Goncalves J
    Kidney Med; 2022 Aug; 4(8):100513. PubMed ID: 36039153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial.
    Fotheringham J; Guest J; Latus J; Lerma E; Morin I; Schaufler T; Soro M; Ständer S; Zeig S
    Patient; 2024 Mar; 17(2):203-213. PubMed ID: 38196014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
    Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
    Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users.
    Shram MJ; Spencer RH; Qian J; Munera CL; Lewis ME; Henningfield JE; Webster L; Menzaghi F
    Clin Transl Sci; 2022 Feb; 15(2):535-547. PubMed ID: 34708917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
    Weiner DE; Vervloet MG; Walpen S; Schaufler T; Munera C; Menzaghi F; Wen W; Bhaduri S; Germain MJ;
    Kidney Med; 2022 Oct; 4(10):100542. PubMed ID: 36185706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
    Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
    J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
    Fukumura K; Yamada T; Yokota T; Kawasaki A
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review.
    Wala K; Szepietowski JC
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
    Zomorodi K; Chen D; Lee L; Lasseter K; Marbury T
    J Clin Pharmacol; 2019 Aug; 59(8):1120-1129. PubMed ID: 30865315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.
    Hoover RK; Alcorn H; Lawrence L; Paulson SK; Quintas M; Luke DR; Cammarata SK
    J Clin Pharmacol; 2018 Jun; 58(6):814-822. PubMed ID: 29578585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
    El-Assal MI; Helmy SA
    Biopharm Drug Dispos; 2014 Oct; 35(7):405-16. PubMed ID: 25044219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
    Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
    Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
    Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of Gepotidacin in Renal Impairment.
    Hossain M; Tiffany C; Raychaudhuri A; Nguyen D; Tai G; Alcorn H; Preston RA; Marbury T; Dumont E
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):560-572. PubMed ID: 32429000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.
    Nafziger AN; Arscott KA; Cochrane K; Skobieranda F; Burt DA; Fossler MJ
    Clin Pharmacol Drug Dev; 2020 Jul; 9(5):639-650. PubMed ID: 31697049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
    Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y
    J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.